dexamethasone cyclodextrin nanoparticle ophthalmic suspension (OCS-01) - Oculis
Multicenter Study on the Efficacy and Safety of OCS-01 in Subjects With Diabetic Macular Edema (clinicaltrials.gov) - Jan 12, 2023 - P2/3 | N=497 | Active, not recruiting | Sponsor: Oculis | Recruiting ➔ Active, not recruiting | Trial completion date: Aug 2024 ➔ Aug 2025 | Trial primary completion date: Jun 2024 ➔ Jun 2025 
Enrollment closed • Trial completion date • Trial primary completion date • Diabetic Macular Edema • Ophthalmology
http://clinicaltrials.gov/ct2/show/NCT05066997
 
Jan 12, 2023
 
Prev Next